Vaccine researcher lays head on the block: "If Pfizer's Covid-19 vaccine works, so will ours"

On Monday, Pfizer and its partner Biontech announced promising results with potential vaccine for Covid-19 aimed at the same protein on which Bavarian Nordic and the vaccine firm Adaptvac are collaborating. The latter is jubilant, having no doubt that the Danish vaccine will work, if Pfizer's does.

Photo: Christian Brasen

Vaccine researchers at the biotech firms Bavarian Nordic and Adaptvac are on the right track with their potential vaccine for Covid-19 and a Danish vaccine will most likely enter the market in spring next year.

This is the estimate coming from the University of Copenhagen researcher Ali Salanti, whose research provides the foundations for the ongoing work at Adaptvac, of which he is a board member.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs